(2022/01/12)
(2021/12/13)
p. 10583 - 10588
(2021/06/25)(2021/11/10)
(2021/10/27)
(2020/05/05)
p. 12382 - 12392
(2020/11/09)(2020/07/13)
p. 1458 - 1461
(2019/08/12)p. 3373 - 3379
(2019/11/11)(2019/10/01)
(2019/01/14)
(2019/03/24)
(2018/10/19)
(2019/01/04)
(2018/11/03)
(2018/10/11)
p. 2832 - 2836
(2017/12/26)(2018/03/26)
(2018/04/01)
(2017/03/28)
(2018/03/24)
(2017/09/06)
(2017/10/07)
(2017/08/01)
(2017/09/01)
(2017/02/24)
(2018/01/13)
(2017/08/23)
(2018/04/11)
p. 17908 - 17922
(2017/12/26)(2017/04/11)
(2016/11/21)
(2017/04/11)
(2016/10/04)
(2016/10/09)
(2015/04/15)
(2014/05/20)
p. 1236 - 1251
(2014/03/21)(2013/11/05)
(2013/11/05)
(2013/10/22)
(2011/04/19)
(2010/05/13)
(2010/04/03)
(2010/04/03)
p. 1145 - 1149
(2008/09/20)(2008/06/13)
(2008/12/07)
(2008/06/13)
dapagliflozin (S) propylene glycol hydrate
L-proline (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyI]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol complex
((2R,3S,4R,5R,6S)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl 4-methylbenzenesulfonate
(2S,3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid
(2S,3R,4R,5S,6S)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(iodomethyl)tetrahydro-2H-pyran-3,4,5-triol